文献速递腹部技术与安全CT

动态肝脏CT强化包膜:LI-RADS v2018诊断HCC的再评估

Enhancing Capsule on Dynamic Liver CT: Association With Hepatocellular Carcinoma Diagnosis Using LI-RADS Version 2018.
PubMed 文献 · AJR Am J Roentgenol · 2026-01-21

该回顾性研究纳入546例肝癌高危患者共645个肝脏观察病灶,均在肝切除或肝移植前1个月内行动态肝脏CT。两位放射科医生分别用LI-RADS v2018原LR-5标准与将强化包膜视同其他主要征象的改良标准进行分级,以病理或≥2年影像随访为参考标准。结果显示改良标准可显著提高HCC诊断敏感度与准确度,特异度与阳性预测值无明显变化。

要点

  • 将强化包膜与其他主要征象同等对待可提升CT诊断HCC敏感度
  • 10–19 mm伴非周边动脉期高强化病灶获益更明显
  • 改良标准未显著降低特异度与阳性预测值

核心结论

  • 在CT上应用LI-RADS v2018时,将强化包膜与其他主要征象同等对待可显著提高HCC检测敏感度,而特异度与阳性预测值无显著变化。
  • 对10–19 mm伴非周边动脉期高强化病灶,改良标准在共识评估下敏感度由52.5%升至64.9%,准确度由56.3%升至66.4%。

研究设计与样本

  • 两位放射科医生独立评估LI-RADS主要征象,分歧经与第三位放射科医生共识讨论解决,参考标准为病理评估或2年以上影像随访。
  • 比较采用广义估计方程,检验原LR-5标准与改良标准之间的诊断性能差异。

关键影像表现/征象

  • 强化包膜在LI-RADS v2018中被列为主要征象,但其诊断权重低于动脉期非周边高强化、非周边廓清与阈值增长。

诊断标准与关键数值

  • 读者1原标准敏感度72.7%、特异度89.2%、阳性预测值96.8%、阴性预测值43.0%、准确度75.2%;改良标准分别为75.7%、88.4%、96.7%、45.5%、77.5%。
  • 读者2原标准敏感度72.8%、特异度91.1%、阳性预测值97.3%、阴性预测值43.6%、准确度75.6%;改良标准分别为75.0%、90.3%、97.1%、45.4%、77.3%。
  • 两位读者改良标准敏感度与准确度均显著高于原标准(p<.05),特异度、阳性预测值与阴性预测值差异无统计学意义(p>.05)。
  • 10–19 mm伴非周边动脉期高强化病灶共识评估:原标准敏感度52.5%、特异度84.0%、阳性预测值95.5%、阴性预测值19.4%、准确度56.3%;改良标准分别64.9%、78.3%、95.1%、23.2%、66.4%。

临床应用与阅片要点

  • CT报告中可将强化包膜作为与其他主要征象等价的LR-5升级条件,有助于提高HCC检出敏感度。
  • 小病灶伴动脉期高强化且可见强化包膜时,可更积极考虑LR-5诊断。
  • 该调整简化LI-RADS判读流程,减少对包膜征象的特殊权重记忆负担。

局限性

  • 单中心回顾性设计,存在选择偏倚与回顾性资料固有局限。
  • 仅纳入接受手术或移植患者,疾病谱向可切除病变倾斜,可能影响阴性预测值等指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. The LI-RADS version 2018 (v2018) diagnostic algorithm prioritizes an enhancing capsule differently from other major features. The role of an enhancing capsule in hepatocellular carcinoma (HCC) diagnosis remains uncertain, particularly for CT. OBJECTIVE. The purpose of this study was to compare the diagnostic performance of CT for diagnosis of HCC using original LI-RADS v2018 criteria for LR-5 versus modified LR-5 criteria that treat an enhancing capsule the same as other major features. METHODS. This retrospective study included 546 patients (432 men and 114 women; mean age, 59.8 ± 9.6 [SD] years) at risk for HCC who underwent dynamic liver CT within 1 month before partial hepatectomy or liver transplant between January 2022 and December 2023. Two radiologists independently assessed hepatic observations (n = 645) for LI-RADS major features; discrepancies were resolved through a consensus discussion with a third radiologist. LI-RADS categories were assigned using original LR-5 criteria and modified criteria giving an enhancing capsule the same priority as other major features (nonperipheral washout and threshold growth). The reference standard was pathologic assessment or 2 or more years of imaging follow-up. Criteria were compared using generalized estimating equations. RESULTS. For reader 1, sensitivity, specificity, PPV, NPV, and accuracy were, respectively, 72.7%, 89.2%, 96.8%, 43.0%, and 75.2% with the use of original LR-5 criteria and 75.7%, 88.4%, 96.7%, 45.5%, and 77.5% with the use of modified criteria, respectively. For reader 2, these values were, respectively, 72.8%, 91.1%, 97.3%, 43.6%, and 75.6% with the use of original criteria and 75.0%, 90.3%, 97.1%, 45.4%, and 77.3% with the use of modified criteria. For both readers, sensitivity and accuracy were significantly higher for modified criteria than for original criteria (p < .05); specificity, PPV, and NPV were not significantly different between the criteria (p > .05). Among observations measuring 10-19 mm with nonrim arterial phase hyperenhancement, when consensus assessments were used, sensitivity, specificity, PPV, NPV, and accuracy were 52.5%, 84.0%, 95.5%, 19.4%, and 56.3%, respectively, when original LR-5 criteria were used and 64.9%, 78.3%, 95.1%, 23.2%, and 66.4%, respectively, when modified criteria were used. CONCLUSION. When LI-RADS v2018 was applied to CT, treating an enhancing capsule the same as other major features provided significantly increased sensitivity for HCC detection without a significant change in specificity or PPV. CLINICAL IMPACT. Treating enhancing capsule the same as other major features for CT-based LI-RADS could improve noninvasive HCC diagnosis while simplifying interpretations.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Choi, Kim, Choi, et al. Enhancing Capsule on Dynamic Liver CT: Association With Hepatocellular Carcinoma Diagnosis Using LI-RADS Version 2018. AJR Am J Roentgenol. 2026. PMID: 41562458. doi:10.2214/AJR.25.34197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。